LEI: 549300Q7EXQQH6KF7Z84
19 January 2021
RTW Venture Fund Limited
(the "Company")
ISSUE OF EQUITY
Today, 19 January 2021, the Company issued 3,575,875 new ordinary shares of no par value each at a price of US$2.12 per share; these shares rank pari passu with the existing ordinary shares in issue. The issue price equates to a premium to the net asset value per share at the time of the transaction.
As a result of this issue, the total number of ordinary shares in issue now stands at 195,091,610 and the total number of voting rights in the Company is 195,091,610. There are no shares held in treasury.
The above figure of 195,091,610 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Company confirms that application for admission will be made to London Stock Exchange plc and it is expected that admission will occur at 8:00 a.m. on 25 January 2021.
William Simpson, who is a Director of the Company, subscribed for 25,000 New Shares. Following this subscription he will hold 125,000 ordinary shares representing c. 0.06% of the enlarged issued ordinary share capital of the Company.
For further information, please contact:
|
RTW Investments, LP Stephanie Sirota, Chief Business Officer Julia Enright, Business Development Associate
|
+1 (646) 343 9280 |
|
J.P. Morgan Cazenove William Simmonds Jérémie Birnbaum James Bouverat (Sales) Charlotte Crowe
|
+44 (0)20 7742 4000 |
|
Ocorian Administration (Guernsey) Limited Kevin Smith |
+44 (0) 1481 742 642 |
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more information.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
